Of GLOW’s three peptides, TB-500 is the one whose name is least settled. Thymosin β4 is a 43-residue protein with a molecular mass of approximately 4963 g/mol (PubChem CID 16132341, listed as timbetasin). Safer, Elzinga and Nachmias (J Biol Chem, 1991) sequenced an actin-sequestering peptide from human platelets, found it identical to thymosin β4, and showed that it binds actin monomers one to one.

TB-500 names something much smaller. A doping-control laboratory at Ghent University analysed a product sold as TB-500 by liquid chromatography with high-resolution mass spectrometry and identified Ac-LKKTETQ, the N-acetylated 17–23 fragment of thymosin β4 (Esposito et al., Drug Testing and Analysis, 2012). PubChem files TB-500 under that fragment. No supplied batch certificate establishes which of these materials is present in this AV-RADIANCE vial.

The evidence on the combination is thin. Curtis’s research review reports that a PubMed search for records naming BPC-157, TB-500 or thymosin β4, and GHK together returned only a few records as of October 16, 2026, all general reviews. No experimental study of the three combined was identified in that review.

Product identity, individual component quantities, purity and batch-specific analytical information should be verified against the applicable supplier documentation and Certificate of Analysis (COA).

Published molecular weights and chemical descriptions provide scientific reference information. They should not be interpreted as proof of the identity, purity or composition of a particular Aevigenix production batch.

FOR NONCLINICAL LABORATORY RESEARCH ONLY.

NOT FOR HUMAN OR VETERINARY USE.

This product is not intended for human consumption, self-administration, veterinary administration, diagnostic applications, treatment or prevention of disease. Product information is provided for scientific identification and laboratory research context only. Research Use Only labeling does not establish regulatory authorization for sale or use.